Merck & Co., Inc. (MRK) operating KPIs

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value

$146.33+5.40 (+3.83%)

Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%

Merck 2024 Restructuring Program (Supply Network & Commercial Optimization) — Total Period Charges Incurred ($M) ($M)

Form 10-Q / 10-K Restructuring Footnote

Quarterly Annual

Latest, FY2025

539

Period ended Dec 31, 2025

Change on a year earlier

-39.3%

888 in FY2024

History

3 years

Since FY2023

Sources

Form 10-K (filed 2026-02-24)

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

Period	Ended	2024 Restructuring Program (Supply Network & Commercial Optimization) — Total Period Charges Incurred ($M) ($M)	Year on year	Source
FY2025	Dec 31, 2025	539	-39.3%	Form 10-K (filed 2026-02-24) ↗
FY2024	Dec 31, 2024	888	+367.4%	Form 10-K (filed 2026-02-24) ↗
FY2023	Dec 31, 2023	190	–	Form 10-K (filed 2026-02-24) ↗

Breakdown

What makes up 2024 restructuring program (supply network & commercial optimization) — total period charges incurred ($m)

Cite this data

StockData. (2026). Merck 2024 Restructuring Program (Supply Network & Commercial Optimization) — Total Period Charges Incurred ($M) ($M), annual FY2023–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/restr_program2024_incurred

See every metric in the Merck KPI table. Data updated Oct 26, 2026.